source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable6 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
locator
title:Cascade-densification deposit: Bapineuzumab Phase III ARIA-E in APOE4 → APOE4-stratified eligibility adoption
imported
2026-05-06T03:57:47.791398+00:00
extraction mode
manual_curation
authors
reviewer:will-blair-bot
Caveats
No source-specific caveats are recorded.
therapeutic · vf_243e224f30408563
review · vf_421b336a4bf3e428
therapeutic · vf_e075a3729ff31c8a
CLARITY-AD lecanemab eligibility required APOE genotyping with specific dosing protocols for APOE4 homozygotes after early ARIA-E rates exceeded 25% in that subgroup; bapineuzumab APOE4 ARIA-E precedent informed design.
AHEAD A3 (NCT04468659) lecanemab preclinical-AD trial protocol mandates APOE genotyping and stratified arm allocation; eligibility design directly references prior anti-Aβ MAb ARIA-E APOE4-dose-dependence including bapineuzumab 302.
FDA labeling for lecanemab (Leqembi) and donanemab (Kisunla) requires APOE genotyping prior to initiation due to APOE4-dose-dependent ARIA-E risk; regulatory framework anchored in earlier MAb-class evidence including bapineuzumab.
events
vev_4f1da193d7812395finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_5290888c0c665c53finding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_52ec2ccaad20968ffinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_627acdeba20eb84ffinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_af2a9505e2363a04finding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_c2ded7975903df6cfinding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_6b3b8f311ce880c3finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_76a4ee28cc03caeffinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_87af01a03b654c44finding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_942d5de98c77d839finding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_c224ecf21fc65b49finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_c52c545b2fae2cbcfinding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation rows are attached.